8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 11, 2021)

Filed January 11, 2021For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced preliminary fourth quarter and full year 2020 financial results via an 8-K filing on January 11, 2021. The report highlights strong net product revenues for its established therapies, ONPATTRO® and GIVLAARI®, which collectively generated approximately $112 million in Q4 2020 and an impressive $361 million for the full year 2020. This indicates continued commercial momentum for these key products. The filing also provides an initial revenue figure for its recently launched product, OXLUMO™, which generated approximately $0.3 million in net product revenues from its late November 2020 U.S. and EU approvals through year-end. While this is a modest start, it represents the beginning of commercial uptake for a new therapy. Furthermore, Alnylam anticipates a robust cash position, with preliminary cash, cash equivalents, and marketable securities estimated at $1.9 billion as of December 31, 2020, providing a strong financial footing for future growth and development.

Key Highlights

  • 1Preliminary Q4 2020 net product revenues for ONPATTRO and GIVLAARI were approximately $112 million.
  • 2Preliminary full year 2020 net product revenues for ONPATTRO and GIVLAARI reached approximately $361 million.
  • 3Initial OXLUMO net product revenues for the period following its late November 2020 approvals were approximately $0.3 million.
  • 4Preliminary cash, cash equivalents, and marketable securities stood at approximately $1.9 billion as of December 31, 2020.
  • 5The reported financial results are preliminary and unaudited, subject to adjustments.
  • 6The information is furnished and not deemed filed for SEC liability purposes.

Frequently Asked Questions

The primary revenue drivers were ONPATTRO® (patisiran) and GIVLAARI® (givosiran), which collectively generated approximately $112 million in preliminary net product revenues for the fourth quarter of 2020.

OXLUMO™ (lumasiran) generated approximately $0.3 million in preliminary global net product revenues during the period following its U.S. and EU approvals in late November 2020 through the end of the year. This represents early commercial uptake for the newly launched therapy.

Alnylam reported a strong preliminary cash position of approximately $1.9 billion in cash, cash equivalents, and marketable securities as of December 31, 2020, indicating significant financial flexibility.

No, the results presented in this filing are preliminary and unaudited. They are subject to adjustment and will be superseded by the company's complete financial results announcement expected in February 2021.